1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Research Antibodies & Reagents Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing research activities by pharmaceutical and biopharmaceutical companies
5.1.1.2. Rising popularity of proteomics and genomics research
5.1.1.3. Emerging trend of research antibodies & reagents in personalized medicine and protein therapeutics
5.1.2. Restraints
5.1.2.1. High cost of antibody development processes
5.1.3. Opportunities
5.1.3.1. Increasing R&D in research antibodies & reagents
5.1.3.2. Rising focus on discovering novel biomarkers
5.1.4. Challenges
5.1.4.1. Quality concerns and a lack of reproducible results of research antibodies & reagents
5.2. Market Segmentation Analysis
5.2.1. Product: Increasing popularity of antibodies for detection and quantification of target proteins
5.2.2. Technology: Increasing usage of research antibodies & reagents in flow cytometry for immunophenotyping
5.2.3. Indication: Expanding application of research antibodies & reagents for identification of pathogens in infectious diseases
5.2.4. Application: Rising utilization of research antibodies and reagents for drug development tailored to specific therapeutic targets
5.2.5. End-user: Expanding usage of research antibodies & reagents across pharmaceutical & biotechnology companies
5.3. Market Trend Analysis
5.3.1. Increasing government investment for drug discovery coupled with robust foothold of major companies in Americas region
5.3.2. Improving healthcare infrastructure and rising investment in life sciences research in the Asia-Pacific region
5.3.3. Expanding government support for research and development in the field of genomics and strong foothold of major biotechnology companies in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Research Antibodies & Reagents Market, by Product
6.1. Introduction
6.2. Antibodies
6.3.1. Monoclonal Antibodies
6.3.2. Polyclonal Antibodies
6.3.3. Recombinant Antibodies
6.3. Reagent
6.4.1. Buffers
6.4.2. Enzymes
6.4.3. Fixatives
6.4.4. Media & Sera
6.4.5. Probes
6.4.6. Solvents
6.4.7. Stains & Dyes
7. Research Antibodies & Reagents Market, by Technology
7.1. Introduction
7.2. Enzyme-linked Immunosorbent Assay
7.3. Flow Cytometry
7.4. Immunofluorescence
7.5. Immunohistochemistry
7.6. Immunoprecipitation
7.7. Western Blotting
8. Research Antibodies & Reagents Market, by Indication
8.1. Introduction
8.2. Immunology
8.3. Infectious Diseases
8.4. Neurobiology
8.5. Oncology
8.6. Stem Cells
9. Research Antibodies & Reagents Market, by Application
9.1. Introduction
9.2. Drug Development
9.3. Genomics
9.4. Proteomics
10. Research Antibodies & Reagents Market, by End User
10.1. Introduction
10.2. Academic & Research Institutions
10.3. Contract Research Organizations
10.4. Pharmaceutical & Biotechnology
11. Americas Research Antibodies & Reagents Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Research Antibodies & Reagents Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Research Antibodies & Reagents Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. Danaher to Acquire Abcam plc
14.3.1.2. Lonza Group Ltd. to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. ERS Genomics & Santa Cruz Biotechnology Enter Into CRISPR/Cas9 Licensing Agreement
14.3.2.2. BD and A*STAR Collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
14.3.2.3. Teknova and Sartorius Look to Address Critical Pain Points in AAV Bioprocessing
14.3.2.4. Bio-Techne And Cell Signaling Technology Announce Partnership To Validate Simple Western Antibodies
14.3.2.5. Cytek Biosciences, Inc. Partners with Bio-Rad Laboratories, Inc. to Expand Reagent Portfolios
14.3.3. New Product Launch & Enhancement
14.3.3.1. GenScript Expands Range of Reagent Services, Adding Circular RNA and Lipid Nanoparticles Formulation
14.3.3.2. Bio-Rad Laboratories, Inc. Extends Range of Antibody Markers Conjugated to StarBright Dyes
14.3.4. Award, Recognition, & Expansion
14.3.4.1. Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. Agilent Technologies Inc.
15.1.3. Alpha Teknova, Inc.
15.1.4. Atlas Antibodies AB
15.1.5. Avantor, Inc.
15.1.6. BASF SE
15.1.7. Becton, Dickinson and Company
15.1.8. Bio-Rad Laboratories, Inc.
15.1.9. Bio-Techne Corporation
15.1.10. bioMérieux S.A.
15.1.11. Cardinal Health, Inc.
15.1.12. Cell Signaling Technology, Inc.
15.1.13. Charles River Laboratories International, Inc.
15.1.14. Danaher Corporation
15.1.15. Dovetail Genomics LLC
15.1.16. Enzo Life Sciences, Inc.
15.1.17. F. Hoffmann-La Roche Ltd.
15.1.18. FUJIFILM Holdings Corporation
15.1.19. GenScript Biotech Corporation
15.1.20. Honeywell International Inc.
15.1.21. Illumia, Inc.
15.1.22. ImmunoPrecise Antibodies Ltd.
15.1.23. Leinco Technologies, Inc.
15.1.24. LifeSpan BioSciences, Inc.
15.1.25. LobaChemie Pvt. Ltd.
15.1.26. Lonza Group Ltd.
15.1.27. Merck KGaA
15.1.28. Omega Bio-tek, Inc.
15.1.29. PerkinElmer, Inc.
15.1.30. QIAGEN N.V.
15.1.31. Randox Laboratories Ltd.
15.1.32. Rockland Immunochemicals, Inc.
15.1.33. Santa Cruz Biotechnology, Inc.
15.1.34. Sino Biological, Inc.
15.1.35. Thermo Fisher Scientific, Inc.
15.1.36. Tokyo Chemical Industry Co., Ltd.
15.1.37. Tosoh Corporation
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
